Gonzalo Crespo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gonzalo Crespo has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Fernández-Carrillo
Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain
2 shared publications - Laura Mensa
Liver Unit, Hospital Clinic, IDIBAPS, Ciberehd, Barcelona, Spain
2 shared publications - Lluis Castells
Liver Unit, Department of Medicine Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona Barcelona Spain
2 shared publications Miquel Navasa
2 shared publications- Sabela Lens
Hospital Clinic Barcelona, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
2 shared publications - Sofía Pérez-Del-Pulgar
Liver Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
2 shared publications
Latest Publications
- 1 May 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (5) , 1009-1012
Successful Continuation of HCV Treatment After Liver Transplantation
Background Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely. Methods Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified. Results The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT. Conclusions Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.
- 1 May 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (5) , 1009-1012
Successful Continuation of HCV Treatment After Liver Transplantation
Background Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely. Methods Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified. Results The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT. Conclusions Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1082
Sa1633 Clinical Outcome of ERCP Without Prior MRCP in Patients With Suspected Biliary Complications After Liver Transplantation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1082
Sa1633 Clinical Outcome of ERCP Without Prior MRCP in Patients With Suspected Biliary Complications After Liver Transplantation
- 1 October 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (2) , 282-285
IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation
- 1 October 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (2) , 282-285
IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation
- Open Access
- 10 January 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (2) , 375-383
Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C
- 10 January 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (2) , 375-383
Open AccessLiver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 59 (2) , 271-278
Imaging of hepatitis C virus infection in liver grafts after liver transplantation
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 59 (2) , 271-278
Imaging of hepatitis C virus infection in liver grafts after liver transplantation
- 1 May 2012
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 35 (5) , 337-343
Uso de boceprevir y telaprevir en pacientes con VHC (aspectos prácticos)
- 1 May 2012
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 35 (5) , 337-343
Uso de boceprevir y telaprevir en pacientes con VHC (aspectos prácticos)